MedTrace Logo

[68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC)

NCT07020806 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-03-23

No results posted yet for this study

Summary

This is a prospective study using \[68Ga\]Ga DOTA-5G PET/CT imaging in patients diagnosed with metastatic/advanced invasive lobular breast cancer (LBC).

Conditions

  • Metastatic Lobular Breast Carcinoma

Interventions

DRUG

[68Ga]Ga DOTA-5G

Patients will be injected with up to 5 mCi of \[68Ga\]Ga DOTA-5G and imaged at 1 and 2 hours post injection.

Sponsors & Collaborators

  • Dr. Helen K Chew, University of California Davis

    collaborator UNKNOWN

  • Dr. Cameron Foster, University of California Davis

    collaborator UNKNOWN

  • Society of Nuclear Medicine and Molecular Imaging

    collaborator UNKNOWN

  • University of California, Davis

    lead OTHER

Principal Investigators

  • Julie Sutcliffe, PhD · University of California, Davis

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-18
Primary Completion
2027-06-30
Completion
2027-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07020806 on ClinicalTrials.gov